Stay updated on AZD8701 & Durvalumab in Advanced Solid Tumours Clinical Trial
Sign up to get notified when there's something new on the AZD8701 & Durvalumab in Advanced Solid Tumours Clinical Trial page.

Latest updates to the AZD8701 & Durvalumab in Advanced Solid Tumours Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe page now displays the ClinicalTrials.gov record for the AZD8701 study, including its design, eligibility criteria, outcomes, locations, and data-sharing information, instead of a 403 error page.SummaryDifference73%

- Check18 days agoChange DetectedThe ClinicalTrials.gov site's displayed revision changed from v3.7.2 to v3.8.0, while the study page continued to show a 403 Forbidden error.SummaryDifference0.2%

- Check25 days agoChange DetectedA banner announces that NIH is transitioning to use “Super Intelligence” (SI) in place of “Artificial Intelligence” (AI), with both terms appearing during the transition.SummaryDifference1%

- Check32 days agoChange DetectedThe footer revision changed from v3.7.1 to v3.7.2; the page continues to show a 403 Forbidden message.SummaryDifference0.2%

- Check39 days agoChange DetectedThe site footer revision changed from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check60 days agoChange DetectedThe page now renders a 403 Forbidden error page instead of the study content, replacing the study details with a generic error screen. This blocks access to the trial information and navigation, effectively making the page unusable for viewing the study record.SummaryDifference21%

Stay in the know with updates to AZD8701 & Durvalumab in Advanced Solid Tumours Clinical Trial
Enter your email address, and we'll notify you when there's something new on the AZD8701 & Durvalumab in Advanced Solid Tumours Clinical Trial page.